United Kingdom-based AstraZeneca's Tagrisso (osimertinib) has improved overall survival in the patients with epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC) in the phase III Flaura trial, it was reported yesterday.
The firm revealed positive overall survival results from the phase III randomised, double-blinded and multi-centre trial of Tagrisso in earlier-untreated patients with locally-advanced or metastatic NSCLC whose tumours have EGFR mutations.
The product showcased a statistically-significant and clinically-meaningful improvement in overall survival, a secondary endpoint in the phase III trial, compared against erlotinib or gefitinib, both of which were previous standard-of-care (SoC) treatments in this setting. With 556 patients across 29 countries, the Flaura study assessed the efficacy and safety of Tagrisso 80mg orally once daily against comparator EGFR-TKIs (either erlotinib [150mg orally, once daily] or gefitinib [250mg orally, once daily]) in earlier untreated patients with locally-advanced or metastatic EGFRm NSCLC. The product is a third-generation and irreversible EGFR-TKI designed to restrict inhibit both EGFR-sensitising and EGFR T790M-resistance mutations, with clinical activity against central nervous system metastases.
The drug has presently secured approval in 74 countries, including the US, Japan and the EU, for first-line EGFRm metastatic NSCLC.
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
Anavex reports positive long-term data for blarcamesine in early Alzheimer's disease
Johnson & Johnson agrees acquisition of Intra-Cellular Therapies Inc
Neuraxpharm acquires Provigil and Nuvigil to expand CNS portfolio
Nuvation Bio secures NMPA approval for taletrectinib in China
JCR Pharmaceuticals and Modalis Therapeutics advance to next phase of joint gene therapy research
PTC Therapeutics submits vatiquinone NDA to US FDA
Mitsubishi Tanabe Pharma forms research collaboration with Dewpoint Therapeutics
IXICO signs commercial agreement with PETNET Solutions to enhance neuroimaging capabilities